Gregory Russotti
Hoofd Techniek/Wetenschap/O&O bij CENTURY THERAPEUTICS, INC.
Vermogen: 1 M $ op 30-04-2024
Profiel
Gregory Russotti is currently an Advisor at Dynamk Capital LLC and the Chief Technology & Manufacturing Officer at Century Therapeutics, Inc. He previously worked at Celgene Corp.
as the VP of Cell Therapy Development and Operations from 2013 to 2019.
Dr. Russotti holds a doctorate degree from Rutgers State University of New Jersey, as well as undergraduate and graduate degrees from Rensselaer Polytechnic Institute.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 06-05-2024 | 385 092 ( 0.59% ) | 1 M $ | 30-04-2024 |
Actieve functies van Gregory Russotti
| Bedrijven | Functie | Begin |
|---|---|---|
| CENTURY THERAPEUTICS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-01-2020 |
Dynamk Capital LLC
 Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Consultant / Adviseur | - |
Eerdere bekende functies van Gregory Russotti
| Bedrijven | Functie | Einde |
|---|---|---|
| CELGENE | Corporate Officer/Principal | 31-12-2019 |
Opleiding van Gregory Russotti
| Rensselaer Polytechnic Institute | Graduate Degree |
| Rutgers State University of New Jersey | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CENTURY THERAPEUTICS, INC. | Health Technology |
| Bedrijven in privébezit | 2 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Dynamk Capital LLC
Dynamk Capital LLC Investment ManagersFinance Dynamk Capital LLC (Dynamk Capital) is a venture capital firm founded in 2017 by Daniella Kranjac and Mario Kranjac. The firm is headquartered in New York, New York. | Finance |